A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
about
Cancer vulnerabilities unveiled by genomic lossThe role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancerPreclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyThe Importance of Ubiquitin E3 Ligases, SCF and APC/C, in Human CancersSystemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and managementTrial Watch: Proteasomal inhibitors for anticancer therapyPathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesotheliomaA phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial.Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumorsBortezomib (Velcadetrade mark) in the Treatment of Multiple MyelomaA phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapyBortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancerPhase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cellsProteasome inhibitors and cardiac cell growthBortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.Cardiotoxicity of the anticancer therapeutic agent bortezomib.Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.A phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers.Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.The role of proteasome inhibition in nonsmall cell lung cancerPhase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphomaLactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003).Regulation of nuclear factor-kappaB in intestinal epithelial cells in a cell model of inflammationThe 26S proteasome complex: an attractive target for cancer therapySubcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
P2860
Q24296821-56DBBEA8-0D43-472B-B0E9-6DB2D553E954Q24794927-7353B6EE-B9AF-48F5-8BB3-87D93922C7CAQ24814325-BC04D0D1-5BED-4C76-801A-F8B37FA149DEQ26777305-E68AFC2C-9DD4-485C-BF38-DA9EF5F4A5CEQ26830695-0B585624-42A0-4BE5-99F2-2B8609916720Q28082910-57156A33-8869-4472-A847-C31693A957C2Q28209990-AFDDFD12-5271-47E5-A55F-FC2DAECBC3D2Q28533736-92EA7FBC-5C8E-4407-8F11-03A0946D24B5Q30252871-BD50666C-F41B-4519-9FB6-222287DAB3D8Q30814901-65538990-D057-443A-B877-505C02C16C5FQ33308317-33B40192-02DF-4F4F-99C1-380579547562Q33378628-A687D7A3-DCCC-4161-96E5-E56AD39CC4A3Q33378902-58D32000-5218-4C5C-93C8-079B7F0F54C5Q33379044-5F9FFE04-D6BB-4C98-8032-3363CB60288FQ33380300-EE381D5B-B926-40AC-A364-F91CA0DBF41BQ33382525-082CEFE7-885F-42F1-A33B-5C50FD83E078Q33388541-09C947E5-075E-4DA0-B344-1910A7106269Q33396761-E4409F00-5290-4FD6-9508-D23E64C5A82CQ33400938-58F99DD1-9D81-4D0A-BF89-1F41DA68264FQ33421241-38F65929-517E-4481-8FD4-84855C9DC521Q33453188-23F4A936-F95E-4377-B54C-24BB91663643Q33554490-2851D051-13C8-4AD5-9ED6-B1912BFD8017Q33747277-F24CE32A-3B5E-4659-8B40-0D2B9CE5ECFBQ33798624-CD4423DF-3C6F-47A7-86AB-62C34E16E921Q33882390-85DB6E04-3D18-49ED-9EAE-1796AEFD7D09Q34206531-7FA2B8B5-39D0-4193-9D69-46C22EC0BCBCQ34241208-36A94187-0019-4E13-B288-9B28BBBFC41FQ34307050-6792B6CD-AFD5-4B9C-AD71-C49E53012929Q34608271-95E4962D-665A-4E8E-8B6F-BC84A3B259FCQ34786865-0B4BF395-BFFE-4A12-AAE1-A77B418E23FCQ34788381-91AE0AAE-57ED-4EF4-976F-9358676E8BECQ35001441-58B3C030-F842-445B-A036-08668622972EQ35050501-DF50B18F-66D3-4A18-B21B-604052AC88B0Q35127221-179373F5-4231-421E-9B95-0DA3FA74D2B8Q35408665-7BDC707C-ADCD-4378-9203-CAACC045FC16Q35561508-27B885E3-B83C-4AF3-B216-D2D5543220D9Q35609369-DF7B491B-22C6-4D5B-8535-B97608962980Q35624079-30E06641-BEF4-4021-8FB5-F7FD89B76012Q35800851-6A7FEFCA-4442-4898-BF77-735E177E1AD6Q35836881-F5C48D09-6BE7-44FE-96CE-DF3F81F049A0
P2860
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A phase I trial of the novel p ...... nced solid tumor malignancies.
@ast
A phase I trial of the novel p ...... nced solid tumor malignancies.
@en
A phase I trial of the novel p ...... nced solid tumor malignancies.
@nl
type
label
A phase I trial of the novel p ...... nced solid tumor malignancies.
@ast
A phase I trial of the novel p ...... nced solid tumor malignancies.
@en
A phase I trial of the novel p ...... nced solid tumor malignancies.
@nl
prefLabel
A phase I trial of the novel p ...... nced solid tumor malignancies.
@ast
A phase I trial of the novel p ...... nced solid tumor malignancies.
@en
A phase I trial of the novel p ...... nced solid tumor malignancies.
@nl
P2093
P1476
A phase I trial of the novel p ...... nced solid tumor malignancies.
@en
P2093
Carol Aghajanian
Christina Canales
Christine S Pien
David R Spriggs
Don S Dizon
Julian Adams
Martee L Hensley
Paul Sabbatini
Peter J Elliott
P304
P407
P577
2002-08-01T00:00:00Z